Should I buy or sell Catalent stock right now?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalent in the last year. There are currently 1 sell rating, 9 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" CTLT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CTLT, but not buy additional shares or sell existing shares. View CTLT analyst ratings or view top-rated stocks .

What is Catalent's stock price target for 2024?

13 Wall Street research analysts have issued 1 year price targets for Catalent's stock. Their CTLT share price targets range from $42.00 to $63.50. On average, they predict the company's share price to reach $52.46 in the next year. This suggests that the stock has a possible downside of 5.9%. View analysts price targets for CTLT or view top-rated stocks among Wall Street analysts .

How have CTLT shares performed in 2024?

Catalent's stock was trading at $44.93 at the start of the year. Since then, CTLT stock has increased by 24.1% and is now trading at $55.77. View the best growth stocks for 2024 here .

Are investors shorting Catalent?

Catalent saw a increase in short interest in March. As of March 15th, there was short interest totaling 7,850,000 shares, an increase of 8.4% from the February 29th total of 7,240,000 shares. Based on an average trading volume of 2,700,000 shares, the short-interest ratio is currently 2.9 days. View Catalent's Short Interest .

When is Catalent's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, June 10th 2024. View our CTLT earnings forecast .

How were Catalent's earnings last quarter?

Catalent, Inc. (NYSE:CTLT) posted its quarterly earnings data on Friday, February, 9th. The company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of ($0.02) by $0.22. The company had revenue of $1.03 billion for the quarter, compared to the consensus estimate of $1.01 billion. Catalent had a negative net margin of 29.91% and a negative trailing twelve-month return on equity of 2.43%. The business's revenue for the quarter was down 10.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.62 earnings per share.

What ETFs hold Catalent's stock?

ETFs with the largest weight of Catalent (NYSE:CTLT) stock in their portfolio include IQ Merger Arbitrage ETF (MNA) , SPDR S&P Pharmaceuticals ETF (XPH) , Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) , AltShares Merger Arbitrage ETF (ARB) , First Trust Merger Arbitrage ETF (MARB) , iShares U.S. Pharmaceuticals ETF (IHE) , VanEck Pharmaceutical ETF (PPH) and ProShares Merger ETF (MRGR) .

What is John R. Chiminski's approval rating as Catalent's CEO?

391 employees have rated Catalent Chief Executive Officer John R. Chiminski on Glassdoor.com . John R. Chiminski has an approval rating of 80% among the company's employees.

What other stocks do shareholders of Catalent own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalent investors own include Abbott Laboratories (ABT) , Pfizer (PFE) , AbbVie (ABBV) , Advanced Micro Devices (AMD) , Johnson & Johnson (JNJ) , NVIDIA (NVDA) , Alibaba Group (BABA) , Bristol-Myers Squibb (BMY) , AT&T (T) and Cisco Systems (CSCO) .

Who are Catalent's major shareholders?

Catalent's stock is owned by many different retail and institutional investors. Top institutional investors include Mountain Pacific Investment Advisers Inc. ID (0.02%), Czech National Bank (0.02%), Hennion & Walsh Asset Management Inc. (0.01%), Clearview Wealth Advisors LLC (0.00%), First Bank & Trust (0.00%) and Los Angeles Capital Management LLC (0.00%). Insiders that own company stock include Alessandro Maselli , Aristippos Gennadios , Associates LP Ta, Charles Lickfold , Gregory T Lucier , John J Greisch , John R Chiminski, John R Chiminski , Jonathan Arnold , Karen Flynn , Kay A Schmidt , Manja Boerman, Mario Gargiulo , Michael A Riley , Michael J Grippo , Michelle R Ryan , Peter Zippelius , Ricardo Pravda , Ricci S Whitlow , Ricky Hopson , Scott Gunther , Steven L Fasman, Steven L Fasman , Thomas P Castellano and Thomas W Hawkeswood . View institutional ownership trends .

How do I buy shares of Catalent?

Shares of CTLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NYSE:CTLT

Catalent (CTLT) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free CTLT Stock Alerts

$55.77

-0.19 (-0.34%)

(As of 04/18/2024 ET)

Compare

Today's Range: $55.74
▼
$56.53
50-Day Range: $55.77
▼
$58.77
52-Week Range: $31.45
▼
$60.20

Volume: 1.06 million shs
Average Volume: 2.59 million shs
Market Capitalization: $10.09 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $52.46

Get Catalent alerts:

Catalent MarketRank™ Stock Analysis

Analyst Rating: Hold
2.15 Rating Score
Upside/Downside: 5.9% Downside
$52.46 Price Target
Short Interest: Healthy
4.15% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.85
Upright™ Environmental Score
News Sentiment: 0.76
Based on 4 Articles This Week
Insider Trading: Selling Shares
$21,749 Sold Last Quarter
Proj. Earnings Growth: 325.00%
From $0.28 to $1.19 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.32 out of 5 stars

Medical Sector

289th out of 919 stocks

Pharmaceutical Preparations Industry

118th out of 405 stocks

1.1

Analyst's Opinion

Consensus Rating
Catalent has received a consensus rating of Hold. The company's average rating score is 2.15, and is based on 3 buy ratings, 9 hold ratings, and 1 sell rating.
Amount of Analyst Coverage
Catalent has only been the subject of 4 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
4.15% of the outstanding shares of Catalent have been sold short.
Short Interest Ratio / Days to Cover
Catalent has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Catalent has recently decreased by 4.33%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Catalent does not currently pay a dividend.
Dividend Growth
Catalent does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Catalent has received a 72.90% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services", "Clinical research services", and "Pharmacovigilance services" products. See details.
Environmental Sustainability
The Environmental Impact score for Catalent is -0.85.

3.2

News and Social Media Coverage

News Sentiment
Catalent has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Catalent this week, compared to 8 articles on an average week.
Search Interest
10 people have searched for CTLT on MarketBeat in the last 30 days. This is an increase of 11% compared to the previous 30 days.
MarketBeat Follows
8 people have added Catalent to their MarketBeat watchlist in the last 30 days. This is an increase of 14% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Catalent insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $21,749.00 in company stock.
Percentage Held by Insiders
Only 0.31% of the stock of Catalent is held by insiders.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Catalent are expected to grow by 325.00% in the coming year, from $0.28 to $1.19 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Catalent is -8.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Catalent is -8.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Growth Ratio
Catalent has a PEG Ratio of 6.02. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Catalent has a P/B Ratio of 2.18. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Catalent Stock (NYSE:CTLT)

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules. The Pharma and Consumer Health segment offers formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations; and oral, nasal, inhaled, and topical dose forms. This segment also provides clinical supply services through manufacturing, packaging, storage, distribution, and inventory management for small-molecule drugs, protein-based biologics, and cell and gene therapies in clinical trials; and pre-clinical screening, formulation, analytical development, and current good manufacturing practices manufacturing at clinical and commercial scale for softgel capsule, Zydis fast-dissolve tablets, oral solid-dose formats, dry powder inhalers, and nasal delivery devices. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply solutions; fill and finish operations for injectable products; and integrated development and product supply chain solutions. It serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was founded in 1933 and is headquartered in Somerset, New Jersey.

CTLT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CTLT Stock News Headlines

March 20, 2024 | insidertrades.com

Insider Selling: Catalent, Inc. (NYSE:CTLT) SVP Sells 387 Shares of Stock

April 17, 2024 | businesswire.com

Robbins LLP Reminds Stockholders it is Investigating the Acquisition of Catalent, Inc. (CTLT)

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 17, 2024 | investors.com

Here's Your Second Chance To Own 7 Leading Stocks Like Nvidia

April 11, 2024 | za.investing.com

Midday movers: Tesla, Coinbase rise; Uber falls

April 11, 2024 | americanbankingnews.com

StockNews.com Begins Coverage on Catalent (NYSE:CTLT)

April 9, 2024 | finance.yahoo.com

Catalent, Inc. (CTLT) Stock Historical Prices & Data - Yahoo Finance

April 8, 2024 | finance.yahoo.com

Novo Nordisk owner refiles U.S. application for approval of Catalent deal

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 8, 2024 | reuters.com

Novo Nordisk parent refiles US application on Catalent deal

April 4, 2024 | markets.businessinsider.com

Beyond The Numbers: 6 Analysts Discuss Catalent Stock

April 2, 2024 | businesswire.com

Invenra Inc. Announces a Strategic Collaboration with Catalent to Co-Discover Novel Bispecific ADCs

March 28, 2024 | finance.yahoo.com

13 Hot Stocks to Invest in According to Wall Street Analysts

March 21, 2024 | yahoo.com

Monroe County drug maker Catalent to cut 130 jobs. What we know

March 16, 2024 | finance.yahoo.com

CTLT Apr 2024 17.500 call

March 16, 2024 | finance.yahoo.com

CTLT Apr 2024 30.000 call

March 13, 2024 | bizjournals.com

Catalent slashes 90 Bay Area jobs

March 12, 2024 | bizjournals.com

Daily Digest: Taco Bells in Oakland make safety moves; Airbnb's camera ban

March 11, 2024 | prnewswire.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Catalent, Inc. - CTLT

March 8, 2024 | msn.com

Novo Nordisk not planning more supply chain acquisitions: report

March 7, 2024 | reuters.com

Novo Nordisk expects Catalent deal to close later this year

March 7, 2024 | businesswire.com

Catalent Publishes Fifth Annual Corporate Responsibility Report, Highlighting Progress and Reinforcing Long-Term Commitment

March 2, 2024 | nasdaq.com

Guru Fundamental Report for CTLT - Benjamin Graham

February 27, 2024 | stockhouse.com

SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates CHRD, KAMN, CTLT, AVRO

February 24, 2024 | prnewswire.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Catalent, Inc. - CTLT

February 24, 2024 | msn.com

Catalent (CTLT) Price Target Increased by 16.25% to 58.46

February 20, 2024 | markets.businessinsider.com

In-Depth Examination Of 5 Analyst Recommendations For Catalent

See More Headlines

Receive CTLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Catalent and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/09/2024
Today: 4/18/2024
Next Earnings (Estimated): 6/10/2024
Fiscal Year End: 6/30/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NYSE:CTLT
CUSIP: N/A
CIK: 1596783
Web: www.catalent.com
Phone: (732) 537-6200
Fax: 732-537-6480
Employees: 17,800
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $52.46
High Stock Price Target: $63.50
Low Stock Price Target: $42.00
Potential Upside/Downside: -6.2%
Consensus Rating: Hold
Rating Score (0-4): 2.15
Research Coverage: 13 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($6.80)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 199.79
P/E Growth: 6.05
Net Income: $-256,000,000.00
Net Margins: -29.91%
Pretax Margin: -34.91%
Return on Equity: -2.43%
Return on Assets: -0.98%

Debt

Debt-to-Equity Ratio: 1.34
Current Ratio: 2.48
Quick Ratio: 1.73

Sales & Book Value

Annual Sales: $4.28 billion
Price / Sales: 2.36
Cash Flow: $3.24 per share
Price / Cash Flow: 17.29
Book Value: $25.58 per share
Price / Book: 2.19

Miscellaneous

Outstanding Shares: 180,740,000
Free Float: 180,178,000
Market Cap: $10.11 billion
Optionable: Optionable
Beta: 1.20

The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

Mr. Alessandro Maselli (Age 52)
President, CEO & Director
Comp: $1.08M
Dr. Aristippos Gennadios Ph.D. (Age 58)
Group President of Pharma & Consumer Health Segment
Comp: $799.26k
Mr. Ricky Hopson (Age 47)
President, Division Head for BioProduct Delivery & Chief of Staff
Comp: $622.12k
Mr. John J. Greisch M.B.A. (Age 69)
Executive Chairman of the Board
Comp: $125k
Mr. Matti M. Masanovich (Age 52)
Senior VP & CFO
Mr. Michael J. Hatzfeld Jr. (Age 50)
VP & Chief Accounting Officer
Mr. Charles Lickfold (Age 50)
Senior VP & Chief Information Officer
Mr. Paul Surdez
Vice President of Investor Relations
Mr. Joseph A. Ferraro J.D. (Age 45)
Senior VP, General Counsel, Chief Compliance Officer & Secretary
Mr. Michael J. Grippo (Age 55)
Senior Vice President of Strategy & Corporate Development

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CTLT Stock Analysis - Frequently Asked Questions

Should I buy or sell Catalent stock right now?: 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalent in the last year. There are currently 1 sell rating, 9 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" CTLT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CTLT, but not buy additional shares or sell existing shares.
View CTLT analyst ratings or view top-rated stocks.
What is Catalent's stock price target for 2024?: 13 Wall Street research analysts have issued 1 year price targets for Catalent's stock. Their CTLT share price targets range from $42.00 to $63.50. On average, they predict the company's share price to reach $52.46 in the next year. This suggests that the stock has a possible downside of 5.9%.
View analysts price targets for CTLT or view top-rated stocks among Wall Street analysts.
How have CTLT shares performed in 2024?: Catalent's stock was trading at $44.93 at the start of the year. Since then, CTLT stock has increased by 24.1% and is now trading at $55.77.
View the best growth stocks for 2024 here.
Are investors shorting Catalent?: Catalent saw a increase in short interest in March. As of March 15th, there was short interest totaling 7,850,000 shares, an increase of 8.4% from the February 29th total of 7,240,000 shares. Based on an average trading volume of 2,700,000 shares, the short-interest ratio is currently 2.9 days.
View Catalent's Short Interest.
When is Catalent's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, June 10th 2024.
View our CTLT earnings forecast.
How were Catalent's earnings last quarter?: Catalent, Inc. (NYSE:CTLT) posted its quarterly earnings data on Friday, February, 9th. The company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of ($0.02) by $0.22. The company had revenue of $1.03 billion for the quarter, compared to the consensus estimate of $1.01 billion. Catalent had a negative net margin of 29.91% and a negative trailing twelve-month return on equity of 2.43%. The business's revenue for the quarter was down 10.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.62 earnings per share.

What ETFs hold Catalent's stock?: ETFs with the largest weight of Catalent (NYSE:CTLT) stock in their portfolio include IQ Merger Arbitrage ETF (MNA), SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), AltShares Merger Arbitrage ETF (ARB), First Trust Merger Arbitrage ETF (MARB), iShares U.S. Pharmaceuticals ETF (IHE), VanEck Pharmaceutical ETF (PPH) and ProShares Merger ETF (MRGR).
What is John R. Chiminski's approval rating as Catalent's CEO?: 391 employees have rated Catalent Chief Executive Officer John R. Chiminski on Glassdoor.com. John R. Chiminski has an approval rating of 80% among the company's employees.
What other stocks do shareholders of Catalent own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Catalent investors own include Abbott Laboratories (ABT), Pfizer (PFE), AbbVie (ABBV), Advanced Micro Devices (AMD), Johnson & Johnson (JNJ), NVIDIA (NVDA), Alibaba Group (BABA), Bristol-Myers Squibb (BMY), AT&T (T) and Cisco Systems (CSCO).
Who are Catalent's major shareholders?: Catalent's stock is owned by many different retail and institutional investors. Top institutional investors include Mountain Pacific Investment Advisers Inc. ID (0.02%), Czech National Bank (0.02%), Hennion & Walsh Asset Management Inc. (0.01%), Clearview Wealth Advisors LLC (0.00%), First Bank & Trust (0.00%) and Los Angeles Capital Management LLC (0.00%). Insiders that own company stock include Alessandro Maselli, Aristippos Gennadios, Associates LP Ta, Charles Lickfold, Gregory T Lucier, John J Greisch, John R Chiminski, John R Chiminski, Jonathan Arnold, Karen Flynn, Kay A Schmidt, Manja Boerman, Mario Gargiulo, Michael A Riley, Michael J Grippo, Michelle R Ryan, Peter Zippelius, Ricardo Pravda, Ricci S Whitlow, Ricky Hopson, Scott Gunther, Steven L Fasman, Steven L Fasman, Thomas P Castellano and Thomas W Hawkeswood.
View institutional ownership trends.
How do I buy shares of Catalent?: Shares of CTLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:CTLT) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Catalent (CTLT) Stock Price, News & Analysis

Catalent MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Catalent Stock (NYSE:CTLT)

CTLT Stock Price History

CTLT Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

CTLT Stock Analysis - Frequently Asked Questions

Overall MarketRank^™